Global Cell-Based Immunotherapy Market 2024

Global Cell-Based Immunotherapy Market 2024

The global cell-based immunotherapy market is likely to register a CAGR of over 14.4% with an incremental growth of USD 5.4 billion during the forecast period 2024-2030. Cell-based immunotherapy, also known as adoptive cell therapy, utilizes immune system cells as therapeutic agents. These cells are extracted from the patient's body, modified or activated, expanded in number, and reintroduced into the patient during treatment. This approach is primarily employed in cancer treatment, targeting specific malignancies. The market for cell-based immunotherapy is dominated by Chimeric Antigen Receptor (CAR) T-Cell Therapy, renowned for its success rates in cancer treatment. Within this market, the B-cell Malignancies segment holds a significant share due to the rising incidence of such malignancies globally.

Key drivers of this market include the increasing prevalence of cancer worldwide, prompting the development of advanced therapies to address this growing health challenge. Targeted therapies, particularly those based on specific cellular targets, are gaining prominence over conventional treatments like chemotherapy and radiotherapy due to their ability to overcome drug resistance and enhance treatment efficacy. Technological advancements in anti-cancer therapies, including CRISPR technology, artificial intelligence, telehealth, advanced assays like the Infinium Assay, cryo electron microscopy, and robotic surgery, are contributing significantly to progress in cancer treatment. These innovations are shaping the landscape of cell-based immunotherapy and improving outcomes for cancer patients globally.

This comprehensive industry report provides market estimates and forecasts, accompanied by a detailed examination of the therapy, primary indication, and region aspects. It delivers a quantitative analysis of the market, empowering stakeholders to leverage existing market opportunities. Furthermore, the report identifies key segments for potential opportunities and strategies, drawing insights from market trends and the approaches of leading competitors.

The global cell-based immunotherapy market has been extensively analyzed by categorizing it according to various sub-segments in order to provide accurate forecasts of industry size and assess trends within specific areas.

The global market for cell-based immunotherapy can be segmented by therapy: autologous cellular immunotherapy, chimeric antigen receptor (CAR) t-cell therapy, dendritic cell (DC)-based vaccine therapy. Globally, the chimeric antigen receptor (CAR) t-cell therapy segment made up the largest share of the cell-based immunotherapy market, representing more than 74.1% of the total market.

Cell-based immunotherapy market is further segmented by primary indication: B-cell malignancies, liver cancer, prostate cancer, renal cell carcinoma (RCC), others. The B-cell malignancies segment captured the largest share of the market in 2023, representing more than 66.3% of the total market.

Based on region, the cell-based immunotherapy market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the highest share in the global cell-based immunotherapy market. However, Asia-Pacific is forecast to register the highest CAGR during the forecast period 2024 - 2030.

The report also provides a detailed analysis of several leading cell-based immunotherapy market vendors that include Bristol-Myers Squibb Company, Celyad Oncology SA, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GC Cell Corporation, Gilead Sciences Inc., Johnson & Johnson, JW Creagene Co., Ltd., Novartis AG, Pfizer Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Why Choose This Report

Gain a reliable outlook of the global cell-based immunotherapy market forecasts from 2024 to 2030 across scenarios.

Identify growth segments for investment.

Stay ahead of competitors through company profiles and market data.

The market estimate for ease of analysis across scenarios in Excel format.

Strategy consulting and research support for three months.

Print authentication provided for the single-user license.

Market Segments Covered in Global Cell-Based Immunotherapy Industry Analysis:

i.) Therapy

• Autologous cellular immunotherapy
• Chimeric antigen receptor (CAR) t-cell therapy
• Dendritic cell (DC)-based vaccine therapy

ii.) Primary indication

• B-cell malignancies
• Liver cancer
• Prostate cancer
• Renal cell carcinoma (RCC)
• Others

iii.) Region

• North America
• Europe
• Asia-Pacific
• MEA (Middle East and Africa)
• Latin America